Patents Assigned to The Children's Medical Center Corp.
-
Patent number: 6060316Abstract: Novel targeting methods of viral entry are disclosed herein.Type: GrantFiled: June 8, 1999Date of Patent: May 9, 2000Assignees: President and Fellows of Harvard College, The Children's Medical Center Corp.Inventors: John A. T. Young, Richard C. Mulligan, Sophie Snitkovsky, Thomas M. J. Niederman
-
Patent number: 6060053Abstract: A method of treatment of vesicoureteral reflux, incontinence and other defects is described wherein chondrocytes are mixed with a liquid biodegradable polymeric material to form a suspension. The suspension is injected into the area where the defect is located and can be corrected by the presence of a bulking agent, in an amount effective to yield cartilage.Type: GrantFiled: May 29, 1996Date of Patent: May 9, 2000Assignees: Children's Medical Center Corp., Massachusetts Institute of TechnologyInventor: Anthony Atala
-
Patent number: 6037138Abstract: Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzymes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of cancer, metastatic cancer, and obstructive and degenerative conditions.Type: GrantFiled: April 25, 1997Date of Patent: March 14, 2000Assignee: The Children's Medical Center Corp.Inventors: Marsha A. Moses, Michael R. Freeman, Dmitri Wiederschain
-
Patent number: 6028061Abstract: The present invention is based on the unexpected discovery that a molecule having as its major repeating units N-acetylglucosamine alternating in sequence with 2-O-sulfated uronic acid, inhibits FGF mitogenicity, and thus is useful in inhibiting angiogenesis. Additionally, the molecule has low toxicity and inhibits FGF mitogenicity without affecting anticoagulant activity. One preferred molecule is a glycosaminoglycan such as archaran sulfate. The molecules are in pharmaceutical compositions that can be used in the treatment of diseases which are angiogenesis-dependent.Type: GrantFiled: June 18, 1998Date of Patent: February 22, 2000Assignees: Children's Medical Center Corp, The University of Iowa Research FoundationInventors: Merton Bernfield, Yeong Shik Kim, Robert J. Linhardt
-
Patent number: 6017954Abstract: This invention relates to methods of using O-substituted fumagillol derivatives or salts thereof preferably, O-(N-chloroacetylcarbamoyl) fumagillol, O-(N-chloroacetylcarbamoyl)dihydrofumagillol or O-(N-chloracetylcarbamoyl)-6'b-hydroxyfumagillol, which have angiogenesis inhibitory activity, in the treatment and prevention of various diseases caused or advanced by abnormally hyperactive angiogenesis, especially various inflammatory diseases (rheumatism, psoriasis, etc.), diabetic retinopathy and cancer and other angiogenesis-dependent tumors, especially Kaposi's sarcoma, breast cancer, colon cancer.Type: GrantFiled: September 3, 1992Date of Patent: January 25, 2000Assignee: Children's Medical Center Corp.Inventors: Moses J. Folkman, Donald Ingber, Takeshi Fujita
-
Patent number: 5968556Abstract: Ground bone or cartilage particles are demineralized by extraction with a low ionic strength buffer such as 20 mM HEPES containing a chelating agent and protease inhibitors, then extracted with an acidic solution such as 0.3 M citric acid, pH 4.0, containing protease inhibitors. The extracted material generally contains less than 2% by weight phosphate and less than 100 mM calcium. The phosphate content can be further reduced by treatment of the matrix with acid phosphatase, which removes residual organic phosphate. The material is useful in a method of treatment of vesicouretal reflux and other disorders where a bulking agent is effective is correcting the defect.Type: GrantFiled: April 2, 1996Date of Patent: October 19, 1999Assignee: Children's Medical Center Corp.Inventors: Anthony Atala, Samy Ashkar
-
Patent number: 5958767Abstract: Stable clones of neural stem cells (NSCs) have been isolated from the human fetal telencephalon. In vitro, these self-renewing clones (affirmed by retroviral insertion site) can spontaneously give rise to all 3 fundamental neural cell types (neurons, oligodendrocytes, astrocytes). Following transplantation into germinal zones of the developing newborn mouse brain, they, like their rodent counterparts, can participate in aspects of normal development, including migration along well-established migratory pathways to disseminated CNS regions, differentiation into multiple developmentally- and regionally-appropriate cell types in response to microenvironmental cues, and non-disruptive, non-tumorigenic interspersion with host progenitors and their progeny. Readily genetically engineered prior to transplantation, human NSCs are capable of expressing foreign transgenes in vivo in these disseminated locations.Type: GrantFiled: August 14, 1998Date of Patent: September 28, 1999Assignee: The Children's Medical Center Corp.Inventors: Evan Y. Snyder, John H. Wolfe, Seung U. Kim
-
Patent number: 5922773Abstract: Elevated glutamate levels are associated with glaucoma, and damage to retinal ganglion cells can be controlled by administering to the patient a compound capable of reducing glutamate induced excitotoxicity in a concentration effective to cause reduction of such excitotoxicity.Type: GrantFiled: December 4, 1992Date of Patent: July 13, 1999Assignees: The Children's Medical Center Corp., Massachusetts Eye and Ear InfirmaryInventors: Stuart A. Lipton, Evan B. Dreyer
-
Patent number: 5851833Abstract: Methods and artificial matrices for the growth and implantation of urological structures and surfaces are disclosed in which urothelial cells are grown in culture on biodegradable, biocompatible, fibrous matrices formed of polymers, such as polyglycolic acid, polylactic acid, or other polymers which degrade over time. The cells can be cultured in vitro until an adequate cell volume and density has developed for the cells to survive and proliferate in vivo. Alternatively, when adequate cell numbers for implantation are available, the cells can be attached to the matrix and implanted directly, without proliferation in vitro. The implants approximate the desired urological structure to be replaced or repaired, such as the kidney, urether, bladder, urethra, and the like. Implantation is followed by remodeling through cell growth and proliferation in vivo.Type: GrantFiled: August 7, 1996Date of Patent: December 22, 1998Assignee: Children's Medical Center Corp.Inventor: Anthony Atala
-
Patent number: 5811393Abstract: Disclosed are heparin binding mitogens which include an epidermal growth factor-homologous segment (HB-EHM). These factors stimulate proliferation of fibroblast cells, epithelial cells, and smooth muscle cells, but not endothelial cells. Also disclosed are isolated antibodies that recognize, and purified nucleic acids that encode, the above growth factors as well as isolated polypeptides, vectors containing such nucleic acids, and cells harboring such vectors. Growth factors of this invention may be used for accelerating the rate of wound healing, for the in vitro culture of HB-EHM-responsive cells, and for the identification of antagonists to HB-EHM.Type: GrantFiled: June 15, 1993Date of Patent: September 22, 1998Assignees: The Childrens Medical Center Corp., Scios Nova, Inc.Inventors: Michael Klagsbrun, Judith A. Abraham, Shigeki Higashiyama, Gail E. Besner
-
Patent number: 5776105Abstract: Systems and methods for delivery of IV fluid to an ambulatory patient are disclosed. The system includes a holder (e.g., a pouch, strap or web-sling) that secures the a source of infusion fluid to a patient's body. Alternatively, the holder can be in the form of a back pack or a fanny pack. The invention further includes a means for applying pressure to the IV fluid to induce infusion. For example, a pressure gradient can be supplied by an infuser bag or a mechanical pressure infuser that is present within the holder or otherwise coupled to an IV fluid container to exert compressive force thereon. The infuser bag can be inflated (e.g., by hand) and may include a valve to prevent over inflation.Type: GrantFiled: September 27, 1996Date of Patent: July 7, 1998Assignee: Children's Medical Center Corp.Inventor: Stephen B. Corn
-
Patent number: 5661143Abstract: The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods.Type: GrantFiled: December 12, 1995Date of Patent: August 26, 1997Assignee: The Children's Medical Center Corp.Inventors: Robert John D'Amato, Moses Judah Folkman
-
Patent number: 4746505Abstract: A bisamide-bisthiol ligand containing fatty acid substituted thiol useful for producing Tc-labelled radiodiagnostic imaging agents is described. The ligand forms a complex with the radionuclide .sup.99m Tc suitable for administration as a radiopharmaceutical to obtain images of the heart for diagnosis of myocardial disfunction.Type: GrantFiled: April 26, 1985Date of Patent: May 24, 1988Assignees: President and Fellows of Harvard College, Children's Medical Center Corp., Massachusetts Institute of TechnologyInventors: Alun G. Jones, John Lister-James, Alan Davison